International Journal of Nuclear Medicine Research  (Volume 4 Issue 2)
 Optimized Production Assessment, Compartmental Modeling and Dosimetric Evaluation of 177Lu- PSMA-617 for Clinical Trials Nuclear
Pages 19-29

Mehdi Sharifi, Hassan Yousefnia, Ali Bahrami-Samani, Amir Reza Jalilian, Samaneh Zolghadri, Mahdokht Vaez-Tehrani and Stephan Maus


Published: 04 December 2017

177Lu-PSMA-617 was prepared at the optimized conditions (95°C, 15-18 µg peptide, 35-40 min; solid phase purification) using 177Lu obtained from 176Lu(n, γ)177Lu reaction(>98%, ITLC, HPLC, S.A. 22-24 TBq/mM) followed by stability (up to 48 h), biodistribution studies (up to 168 h), planar imaging, compartmental modeling and dosimetry estimations via Sparks’s extrapolation method in human organs. Kidney is the critical organ with the dose of 0.067 mGy/MBq and the radiopharmaceutical can be safely used in trials considering the human dose.
Biodistribution, Lu-177, PSMA-617, SPECT imaging, Compartmental modeling.